Serum testosterone - A significant determinant of metastatic relapse for irradiated localized prostate cancer

Urology

Volumn 49, Issue 3, 1997, Pages 327-334

  Zagars, Gunar K ^a   Pollack, Alan ^a   Von Eschenbach, Andrew C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; HORMONE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RELAPSE; TESTOSTERONE BLOOD LEVEL; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; FOLLOW-UP STUDIES; HUMANS; KINETICS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATIC NEOPLASMS; TESTOSTERONE;

EID: 0030891205     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(96)00619-X     Document Type: Article

References (29)

1. Isaacs JT: Role of androgens in prostatic cancer. Vitam Horm 49: 433-502, 1994.
2. Wilding G: Endocrine control of prostate cancer. Cancer Surv 23: 43-62, 1995.
3. Young CYF, Andrews PE, Montgomery BT, and Tindall DJ: Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 31: 818-824, 1992.
4. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, and Smith JA: Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. JAMA 265: 618-621, 1991.
5. Iversen P, Rasmussen F, and Christensen IJ: Serum testosterone as a prognostic factor in patients with advanced pros-tatic carcinoma. ScandJ Urol Nephrol Suppl 157: 41-47, 1994.
6. Roy AV, Brower ME, and Hayden JE: Sodium thymolphthalein monophosphate: a new acid phosphatase substrate with greater specificity for the prostatic enzyme in serum. Clin Chem 17: 1093-1102, 1971.
7. Zagars GK, Geara FB, Pollack A, and von Eschenbach AC: The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy. Cancer 73: 1904-1912, 1994.
8. Harris EK, and Albert A: Survivorship Analysis for Clinical Studies. New York, Dekker, 1991, pp 35-110.
9. Altman DG: Practical Statistics for Medical Research. London, Chapman and Hall, 1991, pp 85-150.
10. Zagars GK, and Pollack A: The fall and rise of prostate-specific antigen. Kinetics of serum prostate-specific antigen levels after radiation therapy for prostate cancer. Cancer 72: 832-842, 1993.
11. Zagars GK, Pollack A, and von Eschenbach AC: Prostate cancer and radiation therapy - the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 33: 23-35, 1995.
12. Bagshaw MA, Cox RS, and Ray GR: Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr 7: 47-60, 1988.
13. Zagars GK, Ayala AG, von Eschenbach AC, and Pollack A: The prognostic importance of Gleason grade in prostatic adenocarcinoma: a long-term follow-up study of 648 patients treated with radiation therapy. Int J Radiat Oncol Biol Phys 31: 237-245, 1995.
14. Partin AW, Pound CR, Clemens JQ, Epstein JI, and Walsh PC: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am 20: 713-725, 1993.
15. Zagars GK, Pollack A, Kavadi VS, and von Eschenbach AC: Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32: 293-306, 1995.
16. Doering CH, Kraemer HC, Brodie HK, and Hamburg DA: A cycle of plasma testosterone in the human male. J Clin Endocrinol Metab 40: 492-500, 1975.
17. Smals AGH, Kloppenborg PWC, and Benraad TJ: Circannual cycle in plasma testosterone levels in man. J Clin Endocrinol Metab 42: 979-982, 1976.
18. Winters SJ: Diurnal rhythm of testosterone and luteinizing hormone in hypogonadal men. J Androl 12: 185-190, 1993.
19. Schrader SM, Turner TW, Breitenstein MJ, and Simon SD: Measuring male reproductive hormones for occupational field studies. J Occup Med 35: 574-576, 1993.
20. Harper ME, Pierrepoint CG, and Griffiths K: Carcinoma of the prostate: relationship of pretreatment hormone levels to survival. Eur J Cancer Clin Oncol 20: 477-482, 1984.
21. Monath JR, McCullough DL, Hart LJ, and Jarow JP: Physiologic variations of serum testosterone within the normal range do not affect serum prostate-specific antigen. Urology 46: 58-61, 1995.
22. Monda JM, Myers RP, Bostwick DG, and Oesterling JE: The correlation between serum prostate-specific antigen and prostate cancer is not influenced by the serum testosterone concentration. Urology 46: 62-64, 1995.
23. Cooper CS, Maclndoe JH, Perry PJ, Yates WR, and Williams RD: The effects of exogenous testosterone on total and free prostate specific antigen levels in healthy young men. J Urol 156: 438-442, 1996.
24. Shain SA, McCullough B, and Nitchuk WN: Primary and transplantable adenocarcinomas of the AXC rat ventral prostate gland: morphologic characterization and examination of C19-steroid metabolism in early-passage tumors. JNCI 62: 313-322, 1979.
25. Pollard M, and Luckert PH: Production of autochthonous prostate cancer in Lobund-Wistar rats by treatments with N-nitroso-N-methylurea and testosterone. JNCI 77: 583-587, 1986.
26. Pollard M, and Luckert PH: Promotional effects of testosterone and high fat diet on the development of autochthonous prostate cancer in rats. Cancer Lett 32: 223-227, 1986.
27. Bosland MC, Prinsen MK, Dirksen TJM, and Spit BJ: Characterization of adenocarcinomas of the dorsolateral prostate induced in Wistar rats by N-methyl-N-nitrosourea, 7,12-dimethylbenzene(a)anthracene, and 3,2-dimethyl-4-amino-biphenyl, following sequential treatment with cyproterone acetate and testosterone propionate. Cancer Res 50: 700-709, 1990.
28. Ichikawa T, Ichikawa Y, Hawkins AL, Griffin CA, Isaacs WB, Oshimura M, Barrett JC, and Isaacs JT: Localization of metastasis suppressor gene(s) for prostate cancer to the short arm of human chromosome 11. Cancer Res 52: 3486-3490, 1992.
29. Kyprianou N, and Isaacs JT: Quantal relationship between prostatic dihydrotestosterone and prostatic cell content: critical threshold concept. Prostate 11: 41-50, 1987.